• 1
    Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006;24:104353.
  • 2
    Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Man Sci 1998;1:13340.
  • 3
    Karnon J. Alternative decision modelling techniques for the evaluation of health care technologies: markov processes versus discrete event simulation. Health Econ 2003;12:83748.
  • 4
    Heeg BM, Damen J, Buskens E, et al. Modelling approaches: the case of schizophrenia. Pharmacoeconomics 2008;26:63348.
  • 5
    Eddy DM. Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. Pharmacoeconomics 2006;24:83744.
  • 6
    Maier P, Funk J, Schwarzer G, et al. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134.
  • 7
    Peeters A, Webers C, PrinsM, et al. Quantifying the effect of intra-ocular pressure reduction on the occurrence of glaucoma. Acta Ophthalmol in press.
  • 8
    American Academy of Ophthalmology Glaucoma Panel. Primary Open-Angle Glaucoma. Preferred Practice Patterns. San Francisco, CA: Americal Academy of Ophthalmology, 2005.
  • 9
    European Glaucoma Society. Terminology and Guidelines for Glaucoma (3rd ed.). Savona, Italy: Dogma, 2008.
  • 10
    Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation (1st ed.). Oxford: Oxford University Press, 2006.
  • 11
    Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24:35571.
  • 12
    Weinstein M, O'Brien B, Hornberger J, et al. Principles of good practice of decision analytic modeling in health care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 2003;6:917.
  • 13
    Kobelt G. Health economics, economic evaluation, and glaucoma. J Glaucoma 2002;11:5319.
  • 14
    Realini T, Fechtner R. 56,000 ways to treat glaucoma. Ophthalmology 2002;109:19556.
  • 15
    Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:171120.
  • 16
    Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 2008;26:13148.
  • 17
    Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 2004;9:11018.
  • 18
    Cooper K, Brailsford S, Davies R. Choice of modelling technique for evaluating health care interventions. J Oper Res Soc 2007;58:16876.
  • 19
    Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006;15:1295310.
  • 20
    Law A, Kelton W. Simulation Modeling and Analysis (3rd ed.). New York: McGraw-Hill, 2000.
  • 21
    Heijl A, Patella V. Essential Perimetry; the Field Analyzer Primer (3rd ed.). Dublin, CA: Carl Zeiss Meditec, 2002.
  • 22
    Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:1019.
  • 23
    Statistics Netherlands (CBS). Mortality rates by age and gender. Available from:[Accessed July 12, 2005.
  • 24
    Heijl A, Leske C, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression; results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:126879.
  • 25
    Drummond M, Sculpher M, Torrance G, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford: Oxford University Press, 2005.
  • 26
    Rodenburg-Van Dieten H. Guidelines for Pharmacoeconomic Research (Version 2006). Diemen: Health Insurance Board, 2005.
  • 27
    Mangione C, Lee P, Gutierrez P, et al. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001;119:10508.
  • 28
    Van Gestel A, Webers C, Beckers H, et al. How does visual field loss in glaucoma affect generic and disease-specific health-related quality-of-life? World Glaucoma Congress, July 8–11, 2009.
  • 29
    McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000;17:50113.
  • 30
    Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 2000;17:46177.
  • 31
    Kass M, Heuer D, Higginbotham E, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocularhypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:70113.
  • 32
    Chen P. Blindness in patients with treated open-angle glaucoma. Ophthalmology 2003;110:72633.
  • 33
    Wilson M, Kosoko O, Cowan C, et al. Progression of visual field loss in untreated glaucoma patients and glaucoma suspects in St. Lucia, West Indies. Am J Ophthalmol 2002;134:399405.
  • 34
    The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing progression of glaucoma from visual field fluctuations. Ophthalmology 2004;111:210916.
  • 35
    Heeg G, Blanksma L, Hardus PLLJ, Jansonius N. The Groningen longitudinal glaucoma study. I. Baseline sensitivity and specificity of the frequency doubling perimeter and the GDx nerve fibre analyser. Acta Ophthalmol Scand 2005;83:4652.
  • 36
    McKean Cowdin R, Varma R, Wu J, et al. Severity of visual field loss and health-related quality of life. Am J Ophthalmol 2007;143:101323.
  • 37
    Rein D, Wittenborn J, Lee P, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 2009;116:82332.